Earnings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences: Sales of Sapien transcatheter aortic heart valves in Europe reach $2 million in the fourth quarter of 2007 and will increase to $20 million in 2008, CEO Michael Mussallem reports Feb. 5. The device gained a CE mark clearance last September and is in clinical trials in the U.S. (1"The Gray Sheet" Feb. 4, 2008, In Brief). Edwards' overall heart valve sales of $131.4 million for the quarter were up 9% from a year ago, led by a "strong" international performance. Critical care segment sales grew 20% to $113 million, led by the FloTrac cardiac output monitoring system. Corporate sales of $293 million were up 10.3% from the fourth quarter of 2006
You may also be interested in...
Edwards’ Sapien Sales Drive 24% Gain In Q2 Heart Valve Revenue
Edwards Lifesciences' heart valve sales soared 24% in the second quarter from a year ago, to $162.6 million, driven by European sales of its Sapien transcatheter heart valve, the company says
Edwards’ Sapien Sales Drive 24% Gain In Q2 Heart Valve Revenue
Edwards Lifesciences' heart valve sales soared 24% in the second quarter from a year ago, to $162.6 million, driven by European sales of its Sapien transcatheter heart valve, the company says
Earnings In Brief
Boston Scientific stent sales reflect growing competition: Boston Scientific's drug-eluting coronary stent sales totaled $428 million in the first quarter, an 8.5% decline from the prior-year period and a 1.6% sequential decrease from the fourth quarter of 2007, the firm reported April 21. The drop was due in part to price cuts and increased competition in the U.S. with the launch in February of Medtronic's Endeavor zotarolimus-eluting stent. Wachovia analyst Larry Biegelsen estimates that Boston Scientific's Taxus paclitaxel-eluting stent ceded four points of U.S. market share to Endeavor during the quarter versus seven points for Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent. Boston Scientific estimates that Endeavor held U.S. share of 12%-13% at the end of the quarter. Despite the market share shift, Chief Operating Officer Paul LaViolette pointed to "clear evidence of recovery" in the drug-eluting stent market. The firm's cardiac rhythm management sales of $565 million in Q1 reflect a 4.8% year-over-year advance